Inbiogen인바이오젠
101140 · KOSPI · ₩101140 · 인바이오젠
₩4,605▼ ₩170 (3.56%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | −10.6% | −5.5% | 9.4% | 21.3% | 19.8% | 18.7% |
| Operating margin | −76.6% | −68.8% | −86.5% | −98.6% | −55.5% | −75.7% |
| Net margin | −78.7% | −22.5% | 229.0% | 181.8% | −1,027.9% | 898.1% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −18.9% | −10.6% | +12.8% | −45.3% | +8.8% | — |
| Operating income growth | +9.7% | +28.9% | +1.0% | +2.9% | +20.2% | — |
| Net income growth | −183.2% | −108.8% | +42.1% | +109.7% | −224.5% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −2.7% | −0.9% | 10.6% | 9.1% | −82.3% | 52.9% |
| Return on assets | −2.6% | −0.9% | 10.5% | 7.8% | −56.0% | 34.3% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 3.8% | 1.5% | 1.8% | 1.8% | 35.0% | 54.2% |
| Net debt to equity | — | — | — | — | −7.8% | −6.5% |
| Current ratio | 137.3% | 285.8% | 438.4% | 536.0% | 46.0% | 41.0% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Inbiogen / 인바이오젠 / 101140 / KRX:101140
Source: KRX statistical information